Treatment of Metastatic Primary Extramammary Paget Disease With Combination Anlotinib and Tislelizumab: A Case Report and Review of the Literature

Treatment of Metastatic Primary Extramammary Paget Disease With Combination Anlotinib and Tislelizumab: A Case Report and Review of the Literature

Extramammary Paget’s disease (EMPD) is a rare cutaneous neoplasm with distant metastases and a poor prognosis. We report the case of a 63-year-old male patient exhibiting stage IV primary EMPD with neuroendocrine differentiation, and harboring a somatic mutation in AMER1. After four cycles of Anloti...

Full description

Bibliographic Details
Main Authors: Xin Yin, Xiaoqing Li, Muli Li, Qing She, Yan Liu, Xiaodan Chen, Suhua Ma, Qian Ma, Zhangkan Huang, Lin Xu, Xiaozhun Huang, Zhengyin Zhan, Xu Che
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Medicine
Subjects:
extramammary Paget disease
anlotinib
tislelizumab
neuroendocrine differentiation
survival
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.891958/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.891958/full

Similar Items